Public company intelligence preview
BNB PLUS CORP
19 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: N/A average total compensation across covered insiders.
Governance movement
Public aggregate: 2 governance events in the last year.
Institutional ownership
Public aggregate: 21 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
BNB Plus Corp. operates in the Healthcare sector and Diagnostics & Research industry, but its business is now split between a legacy biotech platform and a new digital asset treasury strategy. Its LineaRx subsidiary develops nucleic-acid manufacturing technologies for biopharma and diagnostics customers, including platforms for DNA, RNA, and in vitro transcription applications, while the company is increasingly focused on accumulating and yielding BNB, the native token of the Binance ecosystem. Recent filings show a lean operating footprint in New York, significant dependence on third-party service providers, and a business mix that is still producing revenue from DNA manufacturing and related services.
Executive Compensation Practices
Compensation at BNB Plus Corp. is likely influenced by a combination of biotech commercialization milestones and the success of its BNB treasury strategy, rather than traditional revenue growth alone. In a company like this, executives may be rewarded for capital raises, warrant exercises, treasury asset accumulation, and reductions in cash burn, especially since the filings show large SG&A swings tied to consulting arrangements, bonuses, severance, and stock-based compensation. The company’s reported R&D spend, operating losses, and commercialization progress for LineaRx also matter, but near-term pay incentives may be more heavily linked to financing execution and the performance of digital asset holdings.
Insider Trading Considerations
Insider trading patterns in this company may be driven by two highly sensitive themes: biotech development milestones and volatility in BNB-related holdings. Because the company’s reported earnings can be materially affected by fair value changes in BNB, OBNB Trust Units, warrant liabilities, and consulting-related equity awards, insiders may be constrained around periods when treasury positions or financing activity are being updated. Researchers should also watch for trading windows around private placements, warrant exercises, asset rebalancing, and any announcements related to staking, liquidity provision, or sales of crypto assets, since these events can quickly alter reported results and market sentiment.
Unlock the full BNBX insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.